{
    "clinical_study": {
        "@rank": "45470", 
        "brief_summary": {
            "textblock": "RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing\n      so they stop growing or die.\n\n      PURPOSE: Randomized phase I trial to determine the effectiveness of genistein in treating\n      patients who have stage II, stage III, or stage IV prostate cancer."
        }, 
        "brief_title": "Genistein in Treating Patients With Stage II, Stage III, or Stage IV Prostate Cancer", 
        "completion_date": {
            "#text": "May 2003", 
            "@type": "Actual"
        }, 
        "condition": "Prostate Cancer", 
        "condition_browse": {
            "mesh_term": "Prostatic Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "OBJECTIVES: I. Determine the safety and pharmacokinetics of genistein in patients with stage\n      II, III, or IV prostate cancer.\n\n      OUTLINE: This is a randomized, double blind, placebo controlled study. Patients are\n      randomized to one of two treatment arms. Arm I: Patients receive oral genistein twice daily.\n      Arm II: Patients receive oral placebo twice daily. Treatment continues for 3 months in the\n      absence of disease progression or unacceptable toxicity.\n\n      PROJECTED ACCRUAL: A total of 24 patients will be accrued for this study within 6 months."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "DISEASE CHARACTERISTICS: Histologically confirmed stage B, C, or D adenocarcinoma of the\n        prostate not amenable to surgery\n\n        PATIENT CHARACTERISTICS: Age: 40 and over Performance status: ECOG 0-2 Life expectancy: At\n        least 6 months Hematopoietic: WBC at least 3,500/mm3 Platelet count at least 100,000/mm3\n        Hepatic: Bilirubin no greater than 2.0 mg/dL Transaminases less than 4 times upper limit\n        of normal Renal: Creatinine less than 2.0 mg/dL Cardiovascular: No New York Heart\n        Association class III or IV heart disease Other: No significant abnormalities of internal\n        organs, neurologic status, or biochemical levels No history of seizures No concurrent\n        serious illness No acute infection requiring antibiotic therapy except chronic urinary\n        tract infection No other prior or concurrent malignancy within the past 2 years except\n        nonmelanoma carcinoma of the skin No history of substance abuse or addiction No alcohol\n        intake greater than 2 drinks/day or 14 drinks/week No diet containing more than 20 mg of\n        genistein/day No known soy intolerance No prior breast cancer\n\n        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: Not specified\n        Endocrine therapy: At least 3 months since prior hormonal therapy OR No concurrent\n        estrogen Other concurrent hormonal therapy allowed if stable regimen for more than 3\n        months Radiotherapy: At least 4 weeks since prior radiotherapy and recovered Surgery: See\n        Disease Characteristics At least 3 weeks since prior surgery and recovered Other: At least\n        6 weeks since prior antibiotics No concurrent genotoxicity therapy"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "40 Years"
        }, 
        "enrollment": {
            "#text": "0", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "June 2, 2000", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00005827", 
            "org_study_id": "LCCC 9711", 
            "secondary_id": [
                "UNC-GCRC-1203", 
                "NCI-G00-1788", 
                "CDR0000067840"
            ]
        }, 
        "intervention": {
            "intervention_name": "genistein", 
            "intervention_type": "Dietary Supplement"
        }, 
        "intervention_browse": {
            "mesh_term": "Genistein"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "adenocarcinoma of the prostate", 
            "stage II prostate cancer", 
            "stage III prostate cancer", 
            "stage IV prostate cancer", 
            "recurrent prostate cancer"
        ], 
        "lastchanged_date": "April 20, 2012", 
        "location": {
            "facility": {
                "address": {
                    "city": "Chapel Hill", 
                    "country": "United States", 
                    "state": "North Carolina", 
                    "zip": "27599-7295"
                }, 
                "name": "Lineberger Comprehensive Cancer Center, UNC"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase I Single and Multiple-Dose Safety and Pharmacokinetic Clinical Study of Genistein in Normal Volunteers and in Prostate Neoplasia (Multiple Dose Safety and Pharmacokinetic Clinical Study of Genistein in Prostate Neoplasia)", 
        "overall_official": {
            "affiliation": "UNC Lineberger Comprehensive Cancer Center", 
            "last_name": "Leslie Fischer, PhD, MPH, RD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Withdrawn", 
        "oversight_info": {
            "authority": [
                "United States: Federal Government", 
                "United States: Institutional Review Board"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "May 2003", 
            "@type": "Actual"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00005827"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "UNC Lineberger Comprehensive Cancer Center", 
        "sponsors": {
            "collaborator": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "UNC Lineberger Comprehensive Cancer Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 1999", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2012"
    }, 
    "geocoordinates": {
        "Lineberger Comprehensive Cancer Center, UNC": "35.913 -79.056"
    }
}